PuriCore to Present Clinical Case Findings for Vashe(R) Wound Therapy at SAWC
Posted on: Wednesday, 23 April 2008, 09:01 CDT
PuriCore (LSE:PURI), the life sciences company focused on the control of infectious pathogens with its patented, safe, and natural antimicrobial technology, will feature its latest developments and clinical results for its proprietary Vashe Wound Therapy Solution at the Symposium on Advanced Wound Care this week in San Diego, California. PuriCore's technology mimics the human body's production of the natural antimicrobial hypochlorous acid. Hypochlorous acid is highly effective against a broad range of microorganisms including MRSA, VRE, and numerous other bacteria, viruses, and fungal spores.
The Vashe Wound Therapy Solution is designed as a safe and effective non-cytotoxic, non-sensitizing, wound treatment specifically aimed at managing the wound environment. To date, it has been used in more than 2,500 clinical cases including chronic and acute wounds. The data reflect the positive impact the Vashe Wound Therapy Solution has on the wound environment and subsequently, the healing process. Michel H.E. Hermans, MD, a worldwide thought leader in wounds and burn care, will present these clinical results at the PuriCore Booth #1103 throughout the conference.
Additionally, Jeffrey Niezgoda, MD, FACHM, FAPWCA, FACEP, a leading wound management physician, will present three poster/abstracts at this conference related to his clinical experience using the Vashe Wound Therapy Solution as part of the plan of care in managing a broad range of acute and chronic wounds:
"Hypochlorous Acid Solution Improves Wound Healing Trajectories"
"Hypochlorous Acid Solution is Effective in the Treatment of Chronic Venous Ulcers"
"Hypochlorous Acid Enhances the Treatment of Necrotizing Soft Tissue Wounds"
"Our research indicates that hypochlorous acid represents a new and effective class of treatment for hard-to-heal wounds," said Greg Bosch, CEO of PuriCore. "We are very pleased with our promising clinical results showing both safety and potential therapeutic value in the management of such a wide variety of chronic and acute wounds, and we look forward to expanding our clinical work in this area."
About the Vashe Wound Therapy System
PuriCore's patented wound therapy technology is being commercialized as the Vashe Wound Therapy System, a novel, noninvasive, easy-to-use wound management process that has been shown to be complementary to existing treatment methods. The Vashe System is an FDA-cleared medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. The Vashe Solution mimics the human body's own infection fighter, hypochlorous acid. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic antimicrobial and antiseptic products currently used to treat infected wounds and surgical sites and is an important element in the overall clinical process of effective wound management.
About PuriCore
PuriCore (LSE:PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, Avian Influenza, HIV, Polio Virus, Helicobacter pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit PuriCore's website at www.puricore.com, which does not form part of this press release.
Source: Business Wire
Related Articles
- Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
- Stematix Enters into Negotiations With Greek Venture Capital Fund G.I.V.E. - TANEO for Funding of Stem Cell Banks and Therapy Clinics in Greece
- CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
- Lipid Sciences, Inc. Concludes Enrollment in HDL Therapy Clinical Trial
- Additional Studies Further Demonstrate Safety and Efficacy of PuriCore's Vashe(TM) Wound Therapy System
- Surya Singh, MD, Joins D2Hawkeye As Senior Vice President, Client Solutions and Clinical Operations
- Study of PROMETA Protocol Shows Clinical Effectiveness
- Neurologix Announces Positive Interim Results of Landmark Gene Therapy Clinical Trial for Patients With Parkinson's Disease
- Inhibition of Mild Steel By Strontium Chromate in Artificial Acid Rain Solution
- Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial
 |
 |
User Comments (0)
RSS Feeds